The Pistoia Alliance announced key trends for the life science industry in 2019 based on The Life Sciences Innovation Report developed with Clarivate Analytics.

Congrats to Alexandria a BHI partner and Board Member for their commitment to early-stage BioHealth investing.

Alexandria Venture Investments, the strategic venture capital arm of Alexandria Real Estate Equities, Inc. based in Pasadena, was recognized by Silicon Valley Bank as the most active biopharma investor by new deal volume in 2017-2018.

University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that Claire M. Fraser, PhD, a pioneer in the field of microbialgenomics, who is the Dean’s Endowed Professor, Department of Medicine, and Director of the Institutefor Genome Sciences (IGS), has been chosen as president-elect of the American Association for the Advancement of Science (AAAS). AAAS is the world’s largest multidisciplinary scientific society and a leading publisher of cutting edge research through its Science family of journals.

The STSI's 107 individual indicators are sorted into five composites: research and development (R&D) inputs, risk capital and entrepreneurial infrastructure, human capital investment, technology and science workforce, and technology concentration and dynamism.

Maryland placed third on think tank Milken Institute’s 2018 State Technology and Science Index, ranking innovation pipelines. Maryland also placed third in 2016’s report.

The first Food and Drug Administration approvals for cell and gene therapies are already more than a year out, but 2019 is likely to be a significant year for the field, particularly in areas like international interest, industry consolidation and pricing. That was the theme of a panel discussion Monday morning at Biotech Showcase in San Francisco, which coincides with the 2019 J.P. Morgan Healthcare Conference.

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.

What are the top universities in the United States? The list is decided by the CEOWORLD magazine university ranking which considers 7 important factors to help make a balanced comparison. These include influence, reputation, specialization, recruiters Responses and employers Feedback, which in turn help to rate and rank the top unis.

In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell therapy industry.

Now in its 37th year, the conference has ballooned from a small event with 150 attendees that was essentially the " birth of biotech," to an event attended by everyone from the biggest pharma company to the smallest biotech. JPMorgan said more than 485 companies are scheduled to present this year.

Personal Genome Diagnostics is starting off the year with news of a pair of partnership agreements as it looks to expand its approach to cancer testing.

Congratulations to Bahija on making MedImmune the leading BioHealth company in Maryland and accelerating its growth. Also many thanks for the MedImmune longtime support of BHI and helping the BioHealth Capital Region become the 4th largest Life Science region in the country.

Six years after AstraZeneca’s then new CEO Pascal Soriot named Bahija Jallal president of the big MedImmune subsidiary in Gaithersburg, MD, putting her at the center of the company’s R&D turnaround plans, the longtime pharma exec is joining the great migration of industry professionals to biotech.

Bristol-Myers Squibb Co.’s $74 billion planned purchase of Celgene Corp. puts it in line to lead the drug industry’s hottest market, cancer, as early as next year.

Many thanks to Dan for his leadership of Emergent, his service as a loyal BHI Board Member and for helping accelerate the growth of the BIO Health Capital Region

Emergent BioSolutions Inc. (EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to succeed him as president and CEO, effective April 1, 2019. Mr. Abdun-Nabi has also indicated that he plans to step down as a member of the Emergent board of directors, and Emergent expects the board of directors to appoint Mr. Kramer to fill the board vacancy created by Mr. Abdun-Nabi’s retirement.

Here is a significant opportunity for MARYLAND to grow in SBIR success.

One of the best ways to measure the effectiveness of state programs intended to encourage the success of SBIR applications is the approval-rate of their submissions. Although this data has been historically unavailable across every federal agency, it is now accessible for the National Institutes of Health (NIH), the second largest provider of SBIR/STTR awards, according to a 2018 Digest report. The NIH distributed $446.2 million in SBIR/STTR awards in 2017, with every state except North and South Dakota receiving an award. Although California and Massachusetts had the most successful SBIR/STTR applications in 2017, accounting for roughly one-third of the total when combined, neither state ranked among the top 10 in success rate.

A biotechnology venture capital firm is ringing in the new year with its latest fund, having raised a quarter of $1 billion.

Cambridge, Massachusetts-based Atlas Venture said Wednesday that it closed its first Opportunity Fund, or AVOF I, with an oversubscribed fund raise of $250 million. The firm plans to invest the money in companies already in its portfolio.

BrainScope Receives FDA Clearance for Multi-Modal, Multi-Parameter Concussion Assessment

New Concussion-Specific FDA Labeling Adds to Existing BrainScope Claims Complements Multi-Modal Technology Platform and Extensive Intellectual Property Portfolio To Address New Brain and Behavioral Health Conditions

Tuesday, January 15, 2019 8:30AM - 10:30AM

GSK 9911 Belward Campus Drive Rockville, MD 20850

The Maryland Life Sciences, a division of the Maryland Tech Council, brings together vaccine leaders to discuss current breakthroughs in the world of vaccines and immunotherapeutics. This breakfast meeting will address innovating strategies to meet current health threats, changing technology for vaccine manufacturing and provide a snapshot of where vaccine development stands today.

Join us for breakfast, networking and a discussion to hear about the experiences and insights on the current state and projected future of treatments. Local leaders will also discuss challenges and opportunities that come with vaccine and immunotherapy development used by companies in our State.

Different places have different levels of educational achievement.

The American Community Survey is an annual survey run by the Census Bureau to allow the government, corporate and academic researchers, and anyone who is curious about demographics to better understand the US population. Among many other subjects, the ACS includes questions about respondents' education levels.

Though federal agencies are hungry for new technology solutions, a report from the Government Accountability Office says they may be missing out on a key avenue of innovation.

Having analyzed the trends and the shifting winds in the payer marketplace, it’s time to gaze into the crystal ball and see what the future has in store.

“If you can look into the seeds of time, and say which grain will grow and which will not, speak then unto me,” Banquo beseeches the witches in Shakespeare’s “Macbeth,” seeking insight into the future for himself and his closest friend Macbeth.

Peloton tops the list of NYC fund raisers in 2018, followed by WeWork and Letgo.

Though the healthcare field is notoriously slow to adopt new technologies, IT innovation is making its way to the sector. Looking ahead, what does the future of technology in the medical world look like? One hospital executive weighed in.

New funding will support Phase 1 studies for Spiral Therapeutics' lead drug candidate targeting inner ear disorders and hearing loss.

Baltimore startup emocha is working with a local healthcare organization on a new pilot that brings its mobile video technology to Type 2 diabetes patients in the city.

The biopharma industry continues to face challenges this year, with projected returns on investment in R&D at the lowest levels since our analysis began in 2010. However, there are opportunities to reverse this trend, which will require new ways of working and a complete digital transformation to unlock R&D productivity and deliver the next generation of scientific breakthroughs.

The Maryland Department of Commerce is seeking BioHealth companies with an interest in participating in a trade mission to the United Kingdom hosted by British Midlands Engine.

The University of Maryland, Baltimore has granted Educational & Scientific, LLC an exclusive license with the potential to treat prostate cancer, UM Ventures announced Monday. The agreement allows Educational & Scientific to develop Galeterone, a molecule that could inhibit prostate cancer growth in patients with castration-resistant prostate cancer. The molecule has had successful Phase 1 and Phase ...

Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks.

A startup developing new cancer treatments recently signed its second tech transfer deal with the University of Maryland, Baltimore.

After leading Harpoon Medical to a $100 million acquisition by Edwards Lifesciences last year, CEO Bill Niland and three other executives are now working on a fledgling medial device startup creating a minimally invasive treatment for degenerative disc disease in the lower back.

The research institute founded and headed by J. Craig Venter, Ph.D., yesterday won the dismissal of a federal lawsuit filed against it by the company he co-founded four years ago to develop and apply large-scale computing and machine learning toward making discoveries intended to revolutionize the practice of medicine. Judge William Q. Hayes of U.S. District Court for the Southern District of California sided with the J. Craig Venter Institute (JCVI) by dismissing the lawsuit brought against it by Human Longevity Inc. (HLI), the company Venter co-founded in 2014.

General Electric has filed paperwork for an IPO of its health-care unit, GE Healthcare, according to people familiar with the matter.

GE is working with JPMorgan Chase on an initial public offering that would likely come mid-2019, someone familiar with the plans told CNBC. Goldman Sachs, Bank of America, Citigroup and Morgan Stanley are also working with GE, according to Bloomberg News. The new public company would rank among the largest in the world.

State Tech and Science Index - 2018